17 devices · GMDN 56889
Cancer antigen 19-9 (CA19-9) GI IVD antibodies are used to detect a specific protein in clinical specimens, which can help in the diagnosis and monitoring of gastrointestinal and pancreatic cancers. These antibodies are designed to bind to the CA19-9 antigen, allowing for its qualitative and/or quantitative detection. This detection can provide valuable information for healthcare professionals to make informed decisions about patient care.
When browsing this category, it's essential to understand that these devices are subject to regulatory oversight, and their supply and classification are governed by relevant authorities. The regulation of these devices ensures their safety and effectiveness in clinical settings, and they are typically supplied for use in laboratory or clinical environments.
This category summary is AI-generated from the GMDN nomenclature and has not been verified by a human reviewer.